VIATRIS INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
VIATRIS INC. (VTRS) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $1.13 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.13B.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.72B.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $595.00M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $1.19B.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $1.13B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.72B 10-Q · filed 2026-05-07 |
| 2025-09-30 | $595.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.19B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.73B 10-Q · filed 2025-05-08 |
| 2024-09-30 | $580.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.17B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.75B 10-Q · filed 2024-05-09 |
| 2023-09-30 | $573.00M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.18B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.77B 10-Q · filed 2023-05-08 |
| 2022-09-30 | $609.00M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $1.25B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.92B 10-Q · filed 2022-05-09 |
| 2021-09-30 | $661.00M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $1.34B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.00B 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |